Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 1714 • ACR Convergence 2023
Aberrant Myeloid Populations in the TNF-Transgenic Model of Pulmonary Hypertension Overexpress Interferon Pathways and Are Driven by TNFR1 Signaling
Gaochan Wang¹, Qingfu Xu², Stacey Duemmel¹ and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Pulmonary hypertension (PH) is a severe, progressive disorder characterized by elevated pulmonary artery pressures, right ventricular hypertrophy, and increased mortality. We previously demonstrated that…
Abstract Number: 0654 • ACR Convergence 2023
Comparison of Cardiovascular Risk in Patients with Systemic Sclerosis and the General Population
Sabina Oreska¹, Hana Storkanova¹, Jaroslav Kudlicka², Vladimir Tuka², Ondrej Mikes², Zdislava Krupickova², Martin Satny², Eva Chytilova², Jan Kvasnicka², Maja Spiritovic³, Barbora Hermankova⁴, Petr Cesak⁵, Marian Rybar⁶, Karel Pavelka⁷, Ladislav Senolt⁸, Radim Becvar⁹, Jiri Vencovsky¹, Michal Vrablik² and Michal Tomcik¹, ¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁴Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁵Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁶Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic, ⁷Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic, ⁹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: Patients with systemic sclerosis (SSc) may be burdened by increased cardiovascular (CV) risk due to accelerated atherosclerosis (ATS) due to systemic inflammation, and vascular…
Abstract Number: 2037 • ACR Convergence 2023
Assessing Risk of Depression in Common Rheumatologic Disorders Using Diagnostic Codes, Survey Scores, and Propensity Score Matching Methodology
COMFORT ANIM-KORANTENG¹, YONG EUN², Okeoghene Akpoigbe² and AMANDA SAMMUT², ¹Harlem Hospital Center, New York, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Many studies have shown that rheumatologic conditions are associated with a higher risk of depression. The two most common methods to detect depression in…
Abstract Number: 0664 • ACR Convergence 2023
Quantitative Hand Held Dynamometry to Assess Muscle Strength in Scleroderma Associated Myopathy
Julie Paik¹, Christopher Mecoli², Anshula Nallapati¹, Ami Shah³, Fred Wigley⁴, Zsuzsanna McMahan⁵ and Laura Hummers¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ⁴Department of Rheumatology, Johns Hopkins Medicine, Baltimore, MD, ⁵Johns Hopkins Rheumatology, Lutherville, MD
Background/Purpose: Manual muscle strength testing can be challenging in SSc associated myopathy (SSc-AM) due to contractures or skin tightening. Since there is currently no validated…
Abstract Number: 2090 • ACR Convergence 2023
Adaptation of the Making it WorkTM for People with Systemic Sclerosis
Janet Poole¹, Kristine Carandang², Mary Thelander Hill¹, Anna Koch³, Pamela Rogers⁴ and Diane Lacaille⁵, ¹University of New Mexico, Albuquerque, NM, ²University of Wisconsin, San Diego, CA, ³New Mexico Highlands University, Rio Rancho, NM, ⁴Arthritis Research Canada, Richmond, BC, Canada, ⁵Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Systemic sclerosis (SSc) limits participation in paid employment, threatening well-being. Few resources exist to help people with SSc remain in the work force despite…
Abstract Number: 0127 • ACR Convergence 2023
Time Trends, Cumulative Incidence, and Impact on Survival of Interstitial Lung Disease in Systemic Sclerosis: Results from a Population-based Cohort Study
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Cardiopulmonary complications are the number one cause of mortality in Systemic sclerosis (SSc). We studied the prevalence, cumulative incidence, predictors and impact of interstitial…
Abstract Number: 0792 • ACR Convergence 2023
Single Cell RNA-seq of Myeloid Cells from Systemic Sclerosis Patients Identifies Circulating Monocyte Population with Interferon Signature Associated with Interstitial Lung Disease
Richard Ainsworth¹, Kim Taylor², Ye Cao³, Takanori Sasaki⁴, Deepak Rao⁵, Nunzio Bottini⁶ and Francesco Boin¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of California San Francisco, San Francisco, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶University of California, San Francisco, CA
Background/Purpose: Growing evidence supports a critical role for innate immunity in systemic sclerosis (SSc) pathogenesis. Altered myeloid cell numbers and functions have been implicated in…
Abstract Number: 2352 • ACR Convergence 2023
High Serum C-X-C Motif Chemokine Ligand 10 (CXCL10) Potentially Predicts New Onset of Systemic Sclerosis-Interstitial Lung Disease
Yehya Al-Adwi, Isabella Atzeni, Berber Doornbos-van der Meer, Marcel J van der Leij, Bart-Jan Kroesen, Alja Stel, Wim Timens, C.Tji Gan, Harry van Goor, Johanna Westra and Douwe J Mulder, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of death in SSc patients. There is an unmet need for predictive biomarkers of ILD…
Abstract Number: 0128 • ACR Convergence 2023
Incidence, Trends, and Determinants of Multimorbidity in Systemic Sclerosis: Data from a Population-based Cohort
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: To evaluate the burden, longitudinal trends, and drivers of multimorbidity (MM; the presence of ≥2 morbidities) in patients with Systemic Sclerosis (SSc) vs. age-…
Abstract Number: 0935 • ACR Convergence 2023
Sodium Pyruvate Improves Mitochondrial Fitness in SSc Fibroblasts to Prevent Fibroblast-to-myofibroblast Transition and Fibrotic Remodeling
Xiang Zhou¹, Thuong Trinh-Minh¹, Alexandru-Emil Matei¹, Honglin Zhu², Hermina Györfi¹, Cuong Tran Manh¹, Xuezhi Hong¹ and Joerg Distler¹, ¹Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ²3 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. 5 Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: Systematic sclerosis (SSc) is an autoimmune disease characteristic by fibroblast transition and overproduction of extracellular matrix, yet with limited treatment. Recent studies provided evidence…
Abstract Number: 2354 • ACR Convergence 2023
Is Midkine a Novel Biomarker for Acro-osteolysis in Systemic Sclerosis?
Ganiat Adeogun¹, Venkateswara Gogulamudi², Meridith Balbach¹, Anthony Donato² and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Acro-osteolysis is a hand complication in systemic sclerosis (SSc) characterized by the destruction of distal digital bone possibly related to repetitive ischemia-reperfusion injury. Diagnosis…
Abstract Number: 0129 • ACR Convergence 2023
Rising Incidence and High Mortality of Systemic Sclerosis: A Population-based Cohort Study (2010-2020)
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a rare chronic inflammatory disease characterized by immune-mediated dysfunction, vasculopathy and widespread internal organ fibrosis; and the highest case fatality…
Abstract Number: 0948 • ACR Convergence 2023
Nintedanib Alters Fibroblast and Macrophage Diversity in a 3D Skin Model of Systemic Sclerosis (SSc)
Noelle Kosarek¹, Tamar Abel², Sasha Shenk³, Tammara Wood², Jonathan Garlick⁴, Patricia Pioli⁵ and Michael Whitfield⁵, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth College, Hanover, NH, ³Tufts University, Boston, MA, ⁴Tufts University School of Dental Medicine, Boston, MA, ⁵Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs. While the tyrosine kinase inhibitor Nintedanib is…
Abstract Number: 2356 • ACR Convergence 2023
A Macrophage-Specific Mechanism for Mycophenolate Mofetil in the Treatment of Systemic Sclerosis
Emily Morris, Rezvan Parvizi, Patricia Pioli and Michael Whitfield, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by inflammation and fibrosis. Treatment with mycophenolate mofetil (MMF), an inhibitor of lymphocyte…
Abstract Number: 0256 • ACR Convergence 2023
Nintedanib in Combination with Immunosuppressive Agents Improves Forced Vital Capacity in Connective Tissue Disease-associated PF-ILD: A Single-center Study
Yusuke Ushio¹, Risa Wakiya², Tomohiro Kameda², Shusaku Nakashima², Hiromi Shimada², Taichi Miyagi³, Koichi Sugihara⁴, Rina Mino⁵, Mao Mizusaki², Kanako Chujo⁶, Ryoko Kagawa⁷, Hayamasa Yamaguchi⁷ and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁴Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁶Kagawa University, Miki, Kita District, Kagawa, Japan, ⁷Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Japanese patients with connective tissue disease (CTD) are more likely to have interstitial lung disease (CTD-ILD) than those in Western countries and many CTD-ILDs…

« Previous Page
1
…
3
4
5
6
7
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].